Document is current
Any future updates will be listed below
-
Authors
Hu, Zhuting
Leet, Donna E. https://orcid.org/0000-0002-4494-1705
Allesøe, Rosa L.
Oliveira, Giacomo
Li, Shuqiang
Luoma, Adrienne M.
Liu, Jinyan
Forman, Juliet
Huang, Teddy
Iorgulescu, J. Bryan https://orcid.org/0000-0003-1405-3667
Holden, Rebecca
Sarkizova, Siranush
Gohil, Satyen H.
Redd, Robert A. https://orcid.org/0000-0002-1329-5288
Sun, Jing
Elagina, Liudmila
Giobbie-Hurder, Anita
Zhang, Wandi
Peter, Lauren https://orcid.org/0000-0002-2105-7503
Ciantra, Zoe
Rodig, Scott
Olive, Oriol
Shetty, Keerthi
Pyrdol, Jason
Uduman, Mohamed
Lee, Patrick C.
Bachireddy, Pavan
Buchbinder, Elizabeth I.
Yoon, Charles H.
Neuberg, Donna
Pentelute, Bradley L. https://orcid.org/0000-0002-7242-801X
Hacohen, Nir
Livak, Kenneth J. https://orcid.org/0000-0001-9105-5856
Shukla, Sachet A.
Olsen, Lars Rønn
Barouch, Dan H. https://orcid.org/0000-0001-5127-4659
Wucherpfennig, Kai W.
Fritsch, Edward F. https://orcid.org/0000-0002-8412-5665
Keskin, Derin B.
Wu, Catherine J. https://orcid.org/0000-0002-3348-5054
Ott, Patrick A. https://orcid.org/0000-0002-4253-943X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI-5 T32 CA 207021, NCI-R01 CA229261, 5 T32 CA 207021, 5 T32 CA 207021, NCI-R50 CA251956, NCI-K12CA090354, 5P30 CA006516, 5P30 CA006516, 5P30 CA006516, NCI-R50 RCA211482A, NCI-R50 CA251956, NCI P01 CA163222, R21 CA216772-01A1, NCI-U24CA224331, R01CA155010)
Melanoma Research Alliance
NSF Graduate Research Fellowships Program fellowship
Kay Kendall Leukaemia Fund Fellowship
Damon Runyon Cancer Research Foundation
Be The Match Foundation
American Society of Hematology
The Free Research Fund Denmark
- License Information
-
More Information
Article History
Received: 15 June 2020
Accepted: 4 December 2020
First Online: 21 January 2021
Competing interests
: Z.H. is a current employee of ElevateBio. J.S. is a current employee of Moderna Therapeutics. E.F.F. is an equity holder and consultant for BioNTech, and equity holder and SAB member of BioEntre. N.H. and C.J.W. are equity holders of BioNTech. N.H. is a consultant for Related Sciences. P.A.O. has received research funding from and has advised Neon Therapeutics, Bristol-Meyers Squibb, Merck, CytomX, Pfizer, Novartis, Celldex, Amgen, Array, AstraZeneca/MedImmune, Armo BioSciences and Roche/Genentech. C.J.W. is subject to a conflict of interest management plan for the reported studies because of her former competing financial interests in Neon Therapeutics, which was acquired by BioNTech. Under this plan, C.J.W. may not access identifiable data for human subjects or otherwise participate directly in the Institutional Review Board-approved protocol reported herein. C.J.W.’s contributions to the overall strategy and data analyses occurred on a de-identified basis. Patent applications have been filed on aspects of the described work entitled as follows: ‘Compositions and methods for personalized neoplasia vaccines’ (N.H., E.F.F. and C.J.W.), ‘Methods for identifying tumour specific neoantigens’ (N.H. and C.J.W.), ‘Formulations for neoplasia vaccines’ (E.F.F.) and ‘Combination therapy for neoantigen vaccine’ (N.H., C.J.W. and E.F.F.). The DFCI, the lead site of this trial, has a proprietary and financial interest in the personalized neoantigen vaccine. P.B. reports equity in Agenus, Amgen, Breakbio Corp., Johnson & Johnson, Exelixis and BioNTech. S.J.R. receives research support from Merck, Bristol Myers Squibb, Affimed and KITE/Gilead, and is on a scientific advisory board for Immunitas Therapeutics. S.A.S. reported nonfinancial support from Bristol-Myers Squibb outside the submitted work. S.A.S. also previously advised and has received consulting fees from Neon Therapeutics and reported equity in Agenus Inc., Agios Pharmaceuticals, Breakbio Corp., Bristol-Myers Squibb and Lumos Pharma, outside the submitted work. B.L.P. is a founder of Resolute Bio and Amide Technologies; both companies develop protein and peptide therapeutics. E.I.B. consults for Apexigen, Novartis, Partner Therapeutics and receives clinical trial support from Eli Lilly, Novartis, BMS, Genentech and BVD. K.W.W. serves on the scientific advisory board of TCR2 Therapeutics, T-Scan Therapeutics, SQZ Biotech, Nextechinvest and receives sponsored research funding from Novartis. He is a co-founder of Immunitas, a biotech company. These activities are not related to the research reported in this publication. D.B.K. has previously advised Neon Therapeutics and has received consulting fees from Neon Therapeutics. D.B.K. also owns equity in Aduro Biotech, Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceutical, Bristol Myers Squibb, Celldex Therapeutics, Editas Medicine, Exelixis, Gilead Sciences, IMV, Lexicon Pharmaceuticals, Moderna and Regeneron Pharmaceuticals. BeiGene, a Chine biotech company, supports unrelated research at the Translational Immunogenomics Laboratory. The remaining authors declare no competing interests.
